[Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic].
作者信息
Jáuregui Edwin
机构信息
ASOREUMA, Reumatología, Riesgo de fractura S.A-CAYRE IPS, Bogotá, Colombia.
出版信息
Rev Colomb Reumatol. 2021 Apr-Jun;28(2):156-158. doi: 10.1016/j.rcreu.2020.05.004. Epub 2020 Jun 10.
Abstract
摘要
相似文献
1
[Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic].
Rev Colomb Reumatol. 2021 Apr-Jun;28(2):156-158. doi: 10.1016/j.rcreu.2020.05.004. Epub 2020 Jun 10.
2
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
3
Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.
Front Public Health. 2020 May 29;8:252. doi: 10.3389/fpubh.2020.00252. eCollection 2020.
4
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4539-4547. doi: 10.26355/eurrev_202004_21038.
5
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.
6
Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Int Ophthalmol. 2021 Feb;41(2):719-725. doi: 10.1007/s10792-020-01593-0. Epub 2020 Sep 18.
7
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
Arch Pharm Res. 2020 Aug;43(8):765-772. doi: 10.1007/s12272-020-01258-7. Epub 2020 Aug 1.
8
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.
Eur J Ophthalmol. 2021 Mar;31(2):291-303. doi: 10.1177/1120672120958323. Epub 2020 Oct 8.
9
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
Expert Rev Anti Infect Ther. 2020 Nov;18(11):1119-1133. doi: 10.1080/14787210.2020.1792291. Epub 2020 Jul 13.
10
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221. doi: 10.1177/2048872620922784. Epub 2020 May 6.
本文引用的文献
1
Emerging prophylaxis strategies against COVID-19.
Monaldi Arch Chest Dis. 2020 Mar 30;90(1). doi: 10.4081/monaldi.2020.1289.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.
4
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
5
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
6
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
8
Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs.
J Gen Virol. 1969 Mar;4(2):203-14. doi: 10.1099/0022-1317-4-2-203.
Zotero 插件